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Since the discovery of dendritic cells (DCs) by Ralph Steinman
and Zanvil Cohn 40 years ago (1), the role of these cells as critical
regulators of immune tolerance versus activation has emerged as
one of the most fundamental concepts in the field of immunol-
ogy. Serving as a link between the innate and adaptive immune
systems, DCs exhibit sensitive immune surveillance capabilities
that enable their acquisition of antigens from a variety of sources
in peripheral tissues, and they possess unique sensory properties
and antigen processing machinery that enable their transforma-
tion into potent antigen-presenting cells (APCs). Importantly, the
outcome (immune tolerance versus activation) of antigen pre-
sentation to T cells by DC is dependent on the maturation and
activation state of the DC, and significant efforts over the last 20+
years have therefore focused on understanding factors that regulate
DC maturation and activation. While their role in self-tolerance
and the activation of T cell immunity to foreign pathogens has
long been appreciated, more recently DCs have also been shown
to play important roles in the regulation of anti-tumor immune
responses. Since this time, considerable efforts have been placed
on understanding many facets of tumor-associated DC, including:
the induction, regulation, and maintenance of anti-tumor immu-
nity by DC; tumor-associated interference with these processes to
subvert anti-tumor immunity; and the application of this knowl-
edge to develop therapeutic strategies for improving DC-mediated
anti-tumor immune responses. In this collection of articles, we
highlight our current understanding of the role played by DC
in anti-tumor immunity and focus attention on important ques-
tions that remain to be answered in the field as we aim to improve
the immunogenicity of tumor-associated DC and the outcome of
DC-mediated anti-tumor immune responses in the future.
We begin this research topic with an Opinion article by Rolf
Zinkernagel (2) and a responding Commentary from Anne Hos-
malin (3), who offer opposing views on cross-presentation of
tumor antigen by DC that we believe will generate interesting
and thoughtful discussion. These articles are followed by a con-
tribution from Schiavoni et al. (4) reviewing the major subsets of
DC that have been implicated in cross-presentation and the role
of type I IFN in enhancing DC-mediated cross-priming of anti-
tumor CD8+ T cell responses. Research topic co-editor Kristian
Hargadon then reviews the various levels at which tumor cells,
tumor-derived factors, and tumor-associated cells in the milieu
of the tumor microenvironment can interfere with DC function
(5). Mechanistic insights into tumor-altered differentiation of DC
precursors, tumor-associated suppression of DC maturation and
activation, and tumor-induced development of regulatory DC
with immunosuppressive function are highlighted, as are recent
immunotherapeutic strategies that have been designed to pre-
vent or overcome tumor-associated DC dysfunction and enhance
the quality of anti-tumor immune responses. Co-editor Timo-
thy Bullock further examines the metabolic changes that occur
in DC during their maturation and discusses how dysregulated
metabolism, particularly at the level of glycolysis and fatty acid
metabolism, in tumor-associated DC may also impede maturation
and contribute to the diminished immune stimulatory function
of these cells (6). The impact of tumors on DC maturation is
also explored by Dudek et al. (7), who describe the complex-
ity of DC maturation status in the context of tumors, where
the typical dichotomy of immature versus mature DC that reg-
ulate immune tolerance versus activation against clearly “self” or
“non-self” antigen is less obvious. The authors describe a contin-
uum of DC maturation states reported in the context of tumors
that include not only the classical immature, tolerogenic DC
and mature, immunogenic DC but also semi-mature DC which
express low or even moderate levels of costimulatory molecules
but which produce minimal stimulatory cytokines and there-
fore potentiate either tolerogenic or pro-tumorigenic responses.
Studies that have identified factors (cytokines/chemokines, cell
death modalities, and cancer cell-derived danger signals) regulat-
ing tumor-associated DC function are highlighted, as is the ability
of anti-cancer therapeutic agents to influence and modulate the
maturation states of DC. Additional discussion of this topic is pro-
vided by Ott and Bhardwaj (8),who speculate how tumor cell death
resulting from MAPK pathway inhibition might enhance cross-
presentation by DC in BRAFV600 mutant melanoma patients, and
by Palombo et al. (9), who describe various danger-associated mol-
ecular patterns (DAMPs) released during immunogenic cancer
cell death that stimulate inflammatory DC to activate tumor-
specific CD8+ T cell responses. This latter Perspective article
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also discusses evidence for chemotherapy-associated induction of
immune responses, particularly against antigens derived from pro-
teins involved in stress pathways that are normally sequestered in
healthy cells and therefore are not typically processed or presented
to T cells. The authors suggest that such tumor-specific T cells
are likely to be useful tools for identifying novel immunogenic
tumor-specific antigens as these T cells can be isolated and “inter-
rogated” with purified tumor proteins to assess which antigens
are associated with high responsiveness. As researchers consider
how cancer cell death influences immune responses in patients,
and with renewed interest in the potential of combining tradi-
tional cancer therapy and immunotherapy (once thought to be
mutually exclusive approaches to cancer treatment), these arti-
cles highlight the need to better understand how DC respond
(particularly at the level of cytokine secretion) following can-
cer therapies that induce tumor cell death. Such knowledge will
elucidate whether these approaches induce immunogenic versus
tolerogenic cell death and promote development of semi-mature
versus mature DC, and these insights will have significant impli-
cations for optimizing strategies to promote robust anti-tumor
immune activation.
A recurring theme in many of the articles presented herein is
that tumor immune evasion arises not only from a simple fail-
ure of the tumor microenvironment to support DC maturation
but also from an active recruitment and exploitation by tumors
of immature, tolerogenic DC that suppress adaptive responses.
Seliger and Massa (10) review mechanisms by which tumor-
derived soluble and membrane-bound factors alter myeloid and
plasmacytoid DC function, including effects of these molecules
on antigen processing and presentation by DC, T cell stimula-
tory capacity of DC, migration of DC to tumor-draining lymph
nodes, and DC survival. Tesone et al. (11) discuss how tumor-
altered myelopoiesis shifts differentiation of myeloid precursors
from a DC-committed lineage to lineages with immunosuppres-
sive functions such as myeloid-derived suppressor cells (MDSCs)
and tumor-associated macrophages, and these authors also focus
on suppressive mechanisms that prevent DC maturation or that
induce a switch from immunostimulatory to regulatory DC during
tumor progression. Emphasis is also placed on specific recruit-
ment of regulatory DC to tumors by tumor- and stroma-derived
chemoattractants and how these tumor-infiltrating DC contribute
to the overall suppressive nature of the tumor microenvironment.
Vasaturo et al. (12) highlight specifically the negative immune
regulation exhibited by PD-1, CTLA-4, and other co-inhibitory
molecules and their receptors expressed on cells in the tumor
microenvironment, including regulatory DC. These authors bring
to light how such interactions hamper not only the induction of
anti-tumor immunity by tumor-associated, tolerogenic DC that
migrate to draining lymph nodes but also the effector activity
of T cells that may have been activated appropriately in sec-
ondary lymphoid organs but whose effector function is subject to
negative regulation following infiltration of tumors expressing co-
inhibitory molecules. While the authors discuss the potential of
manipulating costimulatory and co-inhibitory molecule expres-
sion in tumors and associated cells as a means of shifting the
milieu of the tumor microenvironment from an immunosuppres-
sive state to an immunostimulatory one, they also address the
potential limitations of non-specifically administering immune
checkpoint inhibitors that may result in autoimmune activation,
thus underscoring the need to better understand ways of fine-
tuning immune regulation by these molecules and of targeting
them in a cell-specific fashion.
Because of the potential of DC to serve as both targets of and
delivery agents for tumor immunotherapies, significant efforts
have been focused on how best to utilize these cells in the treat-
ment of cancer. Gallois and Bhardwaj (13) review mechanisms
by which tumors, Tregs, and immunosuppressive myeloid cells
impair DC function and discuss how interventions that aim to
combat the suppressive tumor microenvironment can improve
the clinical benefit of therapies involving ex vivo-generated DC or
in vivo-targeted DC. In addition to highlighting the need to bet-
ter understand tumor microenvironmental factors that should be
targeted to improve the efficacy of DC-associated immune stim-
ulation in cancer patients, the authors identify a variety of other
factors that must further be studied to optimize these therapies,
including mechanisms of antigen delivery to endogenous DC; the
frequency, route, and site of DC vaccination; methods of DC acti-
vation both ex vivo and in vivo; and the particular DC subsets
that should be employed or targeted during immunization. These
and other factors are considered more specifically in the context
of DC-based therapies in acute and chronic myeloid leukemia
patients by Schürch et al. (14), in ovarian cancer patients by Goyne
and Cannon (15), and in metastatic melanoma patients by van de
Ven et al. (16). Additionally, Ott and Bhardwaj (8) offer insights
into the impact of MAPK pathway inhibition on DC activation
in melanoma patients carrying the BRAFV600 mutation. Finally,
Toubai et al. (17) review the roles of both host and donor DC in
the induction of graft-versus-host disease and graft-versus-tumor
effect following allogeneic hematopoietic stem cell transplanta-
tion, and the authors discuss strategies for, and challenges to,
uncoupling these two processes as a means of maximizing anti-
tumor immunity while minimizing autoimmune reactivity. It is
clear from the work summarized in these articles that while this
field has moved rapidly in recent years, much remains to be learned
to optimize DC-related immune therapies for cancer. Moving for-
ward, it is likely that combinatorial approaches that aim both
to block immune inhibitory pathways and to promote immune
stimulation will ultimately offer the greatest promise for success-
ful DC-based cancer therapies. For instance, while the success of
checkpoint blockade therapy has generally been limited to situa-
tions where T cells are already infiltrating tumors, therapies that
also target DC, either endogenously or via vaccination, will likely
promote anti-tumor T cell activation and therefore increase the
proportion of patients for which checkpoint blockade is a viable
option.
We conclude this collection of articles with a review by
Chmielewski et al. (18), who describe MHC- and APC-
independent immunotherapy using chimeric antigen receptor
(CAR)-redirected T cells as an alternative to DC-based thera-
pies and traditional adoptive T cell transfer therapy. In light of
the tumor-associated suppression of DC described herein and the
requirement for adequate expression of MHC molecules by both
DC and tumor cells to achieve successful anti-tumor immunity,
CAR-redirected T cell therapy has the potential to offer unique
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advantages over traditional immunotherapies by allowing: (1)
the targeting of not only peptides but also carbohydrates and
inorganic compounds expressed on tumor cells and (2) the inclu-
sion of intracellular costimulatory molecule signaling domains in
chimeric receptors that overcomes the limitation inherent in con-
ventional T cell recognition of tumor cells or tumor-altered DC
that typically lack or express low levels of these molecules needed
for T cell activation. Furthermore, although CAR-redirected T cells
bypass the need for stimulation by DC, it is interesting to specu-
late that in addition to their direct anti-tumor activity, these T cells
might also be useful for the licensing of DC in the tumor microen-
vironment, thereby indirectly leading to more robust endogenous
anti-tumor immune responses as well.
As the intricacies of DC biology and the influence of tumors on
DC phenotype and function continue to be uncovered, additional
insights into the role of these cells in the induction, regulation,
and maintenance of anti-tumor immune responses will continue
to shed light on mechanisms of tumor immune escape and inform
the design of novel therapies to enhance anti-tumor immunity. It
is our hope that the advances highlighted herein and the questions
raised for future consideration will generate additional discussion,
drive experimental inquiry, and bring into focus the significance
of tumor/DC interactions and their impact on overall anti-tumor
immunity. Such emphasis is sure to bring rapid advancements
in this field and will ultimately lead to the development of more
effective cancer immunotherapies and improved clinical outcome
in cancer patients in the future.
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